People in this category typically see significant results
For example, in the SELECT trial (17,600 patients with cardiovascular disease and obesity but without T2D), weekly subcutaneous Semaglutide (2.4 mg) reduced the risk of major adverse cardiovascular events (MACE heart attack, stroke, or cardiovascular death) by 20% compared to placebo (HR 0.80
Severe constipation requiring medical treatment or medication discontinuation remains rare, occurring in less than 2% of trial participants
The mean HbA1c change was up to 2.1% with orforglipron 45 mg vs
They also promote changes to hormones that control appetite, allowing people to feel less hungry and more satisfied with smaller amounts of food
Investing in high-purity compounds from a reputable source like Real Peptides is the first and most important step